Breast cancer, Novartis presents results of the Natalee study at the Asco Congress

At the annual meeting of the American Society of Medical Oncology, Novartis presented the results of the pivotal phase III Natalee study, which verified the efficacy of adjuvant therapy with ribociclib in the treatment of women with breast cancer in early stage and high risk of recurrence.